Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA) /tricyclic antidepressant (TCA) combination therapy
Tiller, J.W.; Mitchell, P.; Burrows, G.D.
Australian and New Zealand Journal of Psychiatry 26(2): 327-329
1992
ISSN/ISBN: 0004-8674 PMID: 1642632 DOI: 10.3109/00048679209072051
Accession: 040729271
PDF emailed within 0-6 h: $19.90
Related References
López-Muñoz, F.; Alamo, C.; Juckel, G.; Assion, H-Jörg. 2007: Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors Journal of Clinical Psychopharmacology 27(6): 555-559Kan, J.P.; Benedetti, M.S. 1980: Antagonism between long acting monoamine oxidase inhibitors (MAOI) and MD780515, a new specific and reversible MAOi Life Sciences 26(25): 2165-2171
Morikawa, F.; Ueda, T.; Arai, Y.; Kinemuchi, H. 1986: Inhibition of monoamine oxidase A-form and semicarbazide-sensitive amine oxidase by selective and reversible monoamine oxidase-A inhibitors, amiflamine and FLA 788(+) Pharmacology 32(1): 38-45
Morikawa, F.; Ueda, T.; Arai, Y.; Kinemuchi, H. 1986: Inhibition of monoamine oxidase A-form and semicarbazide sensitive amine-oxidase by selective and reversible monoamine oxidase-A inhibitors, amiflamine and FLA 788(+) Pharmacology 32(1): 33-45
Colzi, A.; D'Agostini, F.; Cesura, A.M.; Borroni, E.; Da Prada, M. 1993: Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo Journal of Pharmacology and Experimental Therapeutics 265(1): 103-111
Snyder, S.H. 1974: Mechanism of antidepressant efficacy of monoamine oxidase inhibitors: inhibition of monoamine oxidase or of catecholamine reuptake Psychopharmacology Bulletin 10(4): 16
Benedetti, M.S.; Dostert, P. 1985: Stereochemical aspects of monoamine oxidase ec 1.4.3.4 interactions reversible and selective inhibitors of monoamine oxidase Trends in Pharmacological Sciences 6(6): 246-251
Berlin, I.; Zimmer, R.; Thiede, H.M.; Payan, C.; Hergueta, T.; Robin, L.; Puech, A.J. 1990: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects British Journal of Clinical Pharmacology 30(6): 805-816
Muehlbauer, B.; Gradin Frimmer, G.; Bieck, P. 1990: Safety of reversible monoamine oxidase inhibitors maoi interaction of brofaromine with sympathomimetic drugs in healthy volunteers Naunyn-Schmiedeberg's Archives of Pharmacology 341(Suppl): R113
Ponto, L.B.; Perry, P.J.; Liskow, B.I.; Seaba, H.H. 1977: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy Journal of the Maine Medical Association 68(8): 283-289
Tolksdorf, W.; Baier, D.; Dingemanse, J. 1992: Monoaminoxydase-Hemmstoffe und RIMA-Substanzen in der Anästhesie - Monoamine oxidase inhibitors and RIMA substances in anaesthesia Anasthesiologie und Intensivmedizin (Erlangen) 33(7): 175-185
Bourgeois, M. 1994: The return of monoamine oxidase inhibitors The new reversible monoamine oxidase inhibitors Widloecher, D , Facy, F , Clodion, M Epidemiology and psychiatry: Confrontation and adaptation to situations of the Caribbean Epidemiologie et psychiatrie: Confrontation et adaptation aux situations de la Caraibe 123-132
Ballesteros, J. 2005: Orphan comparisons and indirect meta-analysis: a case study on antidepressant efficacy in dysthymia comparing tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors by using general linear models Journal of Clinical Psychopharmacology 25(2): 127-131
Andreeva, N.I. 1996: Comparative pharmacological activity of antidepressant agents - inhibitors of reversible type A monoamine oxidase Khimiko-Farmatsevticheskii Zhurnal 30(6): 7-8
Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O. 1962: Behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors Wiener Klinische Wochenschrift 74: 558-559
Pisani, L.; Muncipinto, G.; Miscioscia, T.Fabiola.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. 2009: Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor Journal of Medicinal Chemistry 52(21): 6685-6706
Ponto, L.B.; Perry, P.J.; Liskow, B.I.; Seaba, H.H. 1977: Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy American Journal of Hospital Pharmacy 34(9): 954-961
Ponto, L.B.; Perry, P.J.; Liskow, B.I.; Seaba, H.H. 1977: Drug therapy reviews: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy American Journal of Health-System Pharmacy 34(9): 954-961
Joseph, E.; Berkman, N. 1965: Ocular Complications Due to Monoamine Oxidase Inhibitors (Maoi) La Presse Medicale 73: 1627-1629
Perrault, M. 1965: Monoamine oxidase inhibitors (MAOI) and food products Semaine Therapeutique 41(5): 284-287